Lonn Ryonn PHARMA Ltd.

To evaluate the long-term safety of SM03 in patients with moderately to severely active rheumatoid arthritis who have completed Phase III clinical trials.

To evaluate the tolerability, pharmacokinetics, safety, and efficacy of different doses of LR004 combined with FOLFOX in patients with metastatic colorectal cancer, and to determine the maximum tolerated dose (MTD) of LR004 combined with FOLFOX.

The pharmacokinetic (PK) differences of SYN023 fixed-dose single administration and its combination with rabies vaccine PEP process in Chinese and American subjects were compared to lay the foundation for subsequent clinical trials.